Cargando…
Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers
Purpose: To demonstrate the safety and feasibility of leveraging therapeutic antibodies for surgical imaging. Procedures: We conducted two phase I trials for anti-epidermal growth factor receptor antibodies cetuximab-IRDye800CW (n=12) and panitumumab-IRDye800CW (n=15). Adults with biopsy-confirmed h...
Autores principales: | Gao, Rebecca W., Teraphongphom, Nutte, de Boer, Esther, van den Berg, Nynke S., Divi, Vasu, Kaplan, Michael J., Oberhelman, Nicholas J., Hong, Steven S., Capes, Elissa, Colevas, A. Dimitrios, Warram, Jason M., Rosenthal, Eben L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928904/ https://www.ncbi.nlm.nih.gov/pubmed/29721094 http://dx.doi.org/10.7150/thno.24487 |
Ejemplares similares
-
Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW
por: Krishnan, Giri, et al.
Publicado: (2021) -
Near-Infrared Fluorescence Imaging of EGFR-Overexpressing Tumors in the Mouse Xenograft Model Using scFv-IRDye800CW and Cetuximab-IRDye800CW
por: Amini, Abolfazl, et al.
Publicado: (2022) -
The Use of Panitumumab-IRDye800CW in a Novel Murine Model for Conjunctival Squamous Cell Carcinoma
por: Youn, Gun Min, et al.
Publicado: (2022) -
First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800
por: Miller, Sarah E., et al.
Publicado: (2018) -
Single-Dose Intravenous Toxicity Study of IRDye 800CW in Sprague-Dawley Rats
por: Marshall, Milton V., et al.
Publicado: (2010)